A triple agonist (Retatrutide (GLP-1 + GIP + glucagon) is expected in a couple of years, plus oral versions that could help with dosing are expected to come online over the next couple of years as well
This article explains what GLP-1 balance means, signs of potential dysfunction, natural support strategies, and how this hormone system influences glucose control and satiety
doi: 10.1016/S2213-8587(19)30180-9
No grade 4/5 ICI related adverse events occurred on the waitlist, with 10 (50%) receiving their last ICI dose within one month of LT (median washout 34 days IQR 13.5-55.5)
Qsymia side effects The most common side effects reported in clinical trials include: Paresthesia (tingling or numbness, especially in hands and feet), reported by up to 20% of users at the top dose Dizziness Dysgeusia (altered taste, things taste metallic or strange) Insomnia (due to the stimulant properties of phentermine) Constipation Dry mouth But Qsymia carries several serious warnings that set it apart from GLP-1 medications: Birth defects